Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Mesenchymal stem cell therapy | 1 |
Top 5 Target | Count |
---|---|
COX-2(Cyclooxygenase-2) | 1 |
PAI-1(Plasminogen activator inhibitor 1) | 1 |
Target |
Mechanism COX-2 inhibitors |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date31 Jan 1991 |
Target |
Mechanism PAI-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ACE inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date15 Jan 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TM-5614 ( PAI-1 ) | Philadelphia chromosome positive chronic myelogenous leukemia More | Phase 1 |
Etodolac ( COX-2 ) | Multiple Myeloma More | Preclinical |
Brain tumor (Kidswell Bio) | Brain Cancer More | Discovery |
ATF-HI-8 ( Trypsin x uPA ) | Neoplasms More | Discontinued |
TRA-418 ( PGI2 receptor x TBXA2R ) | Stroke More | Pending |